UroGen Pharma Ltd. URGN
Regular-session close
After hours · Nov 20, 5:25 PM ET
- YTD
- +18.06%
- 1 year
- +11.31%
Held by funds
79 US ETFs and mutual funds hold URGN · largest positions
- ANOIX 0.69% of fund $35.55M
- IWM 0.05% of fund $35.36M
- NJM 0.03% of fund $25.04M
- FSSNX 0.06% of fund $20.08M
- IWO 0.08% of fund $10.96M
- IBB 0.10% of fund $10.25M
- VTWO 0.05% of fund $8.20M
- NLO 0.05% of fund $7.29M
- FESM 0.11% of fund $7.08M
- SPDW 0.02% of fund $6.21M
- VEVFX 0.39% of fund $5.32M
- IWC 0.37% of fund $4.11M
- VHT 0.02% of fund $3.93M
- IJE 0.20% of fund $2.78M
- MDSKX 0.05% of fund $2.61M
- IZRL 1.87% of fund $2.08M
- VFMO 0.10% of fund $1.86M
- IWN 0.01% of fund $1.78M
- NAJ 0.01% of fund $1.65M
- FECGX 0.10% of fund $1.55M
Ownership
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 9.26% | 4,543,895 | 125.64M | Sep 29, 2026 |
| Blackrock Inc. | 6.34% | 3,108,202 | 85.94M | Sep 29, 2026 |
| Kynam Capital Management, LP | 4.96% | 2,434,207 | 67.31M | Sep 29, 2026 |
| Jefferies Financial Group Inc. | 4.48% | 2,199,652 | 60.82M | Sep 29, 2026 |
| Morgan Stanley | 4.43% | 2,174,808 | 60.13M | Sep 29, 2026 |
| SG Americas Securities, LLC | 4.19% | 2,052,906 | 56.76M | Jun 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 1,103,214 | 30.50M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.78% | 874,981 | 24.19M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.95% | 466,099 | 12.89M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.70% | 343,762 | 9.51M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.66% | 323,796 | 8.95M | Sep 29, 2026 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.50% | 244,145 | 6.75M | Aug 30, 2026 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Leadership team
Who runs URGN, and what each was last paid
Elizabeth A. Barrett, President, Chief Executive Officer & DirectorAverage age 58
| Name | Title | Pay | Age |
|---|---|---|---|
| Elizabeth A. Barrett | President, Chief Executive Officer & Director | $2.19M | 64 |
| Jason Drew Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | $978K | 54 |
| Mark Schoenberg | Chief Medical Officer | $730K | 68 |
| Christopher Degnan | Chief Financial Officer | $562K | 46 |
| Marina Konorty | Executive Vice President of Research & Development and Technical Operations | — | — |
| James Ottinger | Executive Vice President of Regulatory Affairs & Quality | — | — |
| Michael J. Louie | Chief Development Officer | — | — |
| Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy | — | — |
| Alison Hardgrove | Senior Vice President of Human Resources | — | — |
| Vincent I. Perrone | Senior Director of Investor Relations | — | — |
Pay is the latest total FMP has for each person (salary, bonus, stock and other awards) and can lag the newest proxy statement. Source: Financial Modeling Prep, from the company’s SEC filings.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BUTITTA CYNTHIA M | Director | Conversion of Exercise of derivative security | Nov 25, 2025 | 2,000 |
| DEGNAN CHRISTOPHER | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 7, 2025 | 2,280 |
| HOLDEN STUART M.D. | Director | Conversion of Exercise of derivative security | Nov 25, 2025 | 2,000 |
| ROBINSON JAMES A JR. | Director | Conversion of Exercise of derivative security | Aug 25, 2026 | 8,000 |
| SCHOENBERG MARK | Officer | Sale | Sep 7, 2026 | 59,882 |
| SMITH JASON DREW | General Counsel | Sale | Sep 7, 2026 | 53,141 |
